New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
08:17 EDTBIIB, ISISIsis Pharmaceuticals data compelling, says BMO Capital
BMO Capital believes that data from a Phase I test of Isis' (ISIS) and Biogen's (BIIB) ISIS-SMN-Rx, an antisense oligonucleotide, for children with spinal muscular atrophy, suggests that the drug has a substantial clinical benefit. The firm raised its price target on Isis to $22 from $17 and maintains an Outperform rating.
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
09:40 EDTISISIsis Pharmaceuticals participates in a conference call with JPMorgan
Subscribe for More Information
May 21, 2015
10:58 EDTBIIBDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 15, 2015
09:31 EDTBIIBAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 13, 2015
07:32 EDTBIIBBiogen names Matt Griffiths as CIO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use